| Today's Big NewsOct 19, 2022 |
|
Greater Philadelphia offers bioscience companies space to develop in close proximity to its world-class University City research center and global airport. From production to R&D, learn how the region can be your launchpad for growth and expansion. 
|
|
| By Angus Liu In perhaps the most indirect way, Johnson & Johnson is warning about layoffs ahead. As the company is about to bid farewell to consumer health, it's looking at the opportunity to "rightsize" the infrastructure, CFO Joe Wolk said. |
|
|
|
By Andrea Park President Joe Biden may have declared the COVID-19 pandemic “over” in the U.S., but that news doesn’t appear to have reached the makers of diagnostic tests for the virus. |
By Dave Muoio Kaiser Permanente's Northern California mental health workers have been off the job since Aug. 15. Hawaiian psychologists, psychiatric nurses and other mental health workers are not included in the tentative deal and remain on strike, a union spokesperson said. |
By Nick Paul Taylor Jazz Pharmaceuticals has thrown its hat into the HER2 ring. For $50 million, the company has secured the chance to pay a further $325 million to take Zymeworks’ HER2-directed bispecific antibody forward after the release of pivotal data. |
By Kevin Dunleavy Merck KGaA’s problems in France over its thyroid drug Levothyrox aren’t going away. Seven months after France’s highest court confirmed an earlier civil court ruling that ordered the Germany-based company to compensate users who suffered problems from Levothyrox, the case has advanced at the judicial level. On Tuesday, a judge in Marseille opened a formal probe to determine if the company provided misleading information when switching the formulation of Levothyrox. |
By Annie Burky Providers are leveraging the power of virtual care and the social insights of population health frameworks and social determinants of health to create care strategies for underserved populations. Similar to the pandemic-era move to population-specific behavioral care with teletherapy platforms, Cityblock, Spora and Zócalo Health are taking a holistic look at patients, while Acclinate's subsidiary NowIncluded works to create unbiased data and care. |
By Max Bayer With $20 million on hand and the second part of a potentially registrational phase 2/3 study just getting underway, Ayala was facing a potential cash crunch. But Advaxis may have solved its problems—in return for the hope of a return to the Nasdaq. |
By Andrea Park Just a few weeks after racking up its fifth Class I recall from the FDA this year, Philips has hit the half-dozen mark. |
By James Waldron The FDA has pumped the brakes on PTC Therapeutics’ Huntington's disease trial in the U.S. even as the studies kick into gear in other countries. |
By Paige Minemyer The company released its quarterly earnings report on Wednesday morning. Profits were up 7.2% from the prior-year quarter, where Elevance Health posted $1.5 billion. |
By James Waldron Ambrx has been mulling major changes since August. Now it has confirmed what form these will take: narrowing its cancer pipeline to earlier-stage therapies and dumping its lead asset at the expense of 15% of its workforce. |
By Fraiser Kansteiner As GSK looks to cement its vaccine dynasty over the coming years, the company continues to polish its “crown jewel” Shingrix. Now, a fresh batch of long-term data suggests the shot’s protective luster lasts at least a decade. |
By Conor Hale That includes green lights for minimally invasive procedures in general surgery, urology and gynecology that the medtech giant estimates currently account for more than 80% of robotic-assisted surgeries worldwide. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about our latest analysis on the world’s most productive biopharmas. We also discuss Biogen's tumultuous year and who it is considering for a new CEO. |
|
|---|
|
|
|
Wednesday, October 26, 2022 | 1pm ET / 10am PT In this webinar, we’ll explore how incorporating telehealth genetic screening into clinical trials can accelerate patient identification, recruitment and engagement. Register now. 
|
|
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
